



Actionable Patients: FDA Approvals

Clinical Decision Support

CancerLinQ identifies patients who may qualify for a newly FDA-approved targeted therapy. This new addition to the Actionable Patients feature presents patients for clinician review to evaluate and confirm eligibility.

 The FDA approvals feature is powered by structured biomarker results flowing into CancerLinQ. Upgrades to your CancerLinQ data integration may be required to realize the full impact of this new tool. Contact your account manager to learn more.



Intelligent Notifications Delivered to Your Inbox

CancerLinQ will notify clinical users when patients match to a therapy or new indication included in this feature. Weekly emails alert you if you have new patient matches. Seamlessly launch the FDA Approval tool directly from the email.

Organize and Manage Your Patients

Manage and monitor your patients based on their latest status: Track patients for whom you plan to prescribe the therapy in the future, set yourself timely reminders, and/or save patients for future review.

Monitor Your Partial Matches

Review patients who match to all clinical criteria as indicated on the FDA label except for biomarker results. Quickly enter missing results directly in the application to update the patient, or use tool to identify testing opportunities.



Receive alerts and seamlessly launch the tool directly from your email



Watch for potentially matching patients



Organize your patients into worklists



View patients who have received the therapy

FDA Approvals tool and reports (together, "information") is offered on an "as is" basis to assist providers who voluntarily choose to access it. The information does not recommend any course of action. The FDA Approvals tool should not be relied upon as being complete or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. The information is not intended to substitute the independent professional judgment of the treating provider. CancerLinQ (i) assumes no liability related to the voluntary use of information; (ii) provides no warranty, express or implied, regarding the information; (iii) disclaims any warranties, including for merchantability or fitness for a particular use or purpose, and (iv) assumes no responsibility for any injury or damage to persons or property arising out of or relating to use of this information, or for any errors or omissions. You may not share, distribute, or disclose any Report, or otherwise use any Report for the benefit of any Third Party, except as explicitly permitted in the Participation Agreement.

For more information on SmartLinQ and the FDA Approvals tool, email info@cancerlinq.org.